CN111108098A - 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法 - Google Patents

一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法 Download PDF

Info

Publication number
CN111108098A
CN111108098A CN201880059079.1A CN201880059079A CN111108098A CN 111108098 A CN111108098 A CN 111108098A CN 201880059079 A CN201880059079 A CN 201880059079A CN 111108098 A CN111108098 A CN 111108098A
Authority
CN
China
Prior art keywords
formula
ray powder
diffraction pattern
powder diffraction
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880059079.1A
Other languages
English (en)
Other versions
CN111108098B (zh
Inventor
翟丽娟
杜振兴
王立坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111108098A publication Critical patent/CN111108098A/zh
Application granted granted Critical
Publication of CN111108098B publication Critical patent/CN111108098B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明涉及一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法。具体而言，本发明涉及一种如式(I)所示的炔基吡啶类脯氨酰羟化酶抑制剂的新晶型。本发明的新晶型具备良好的稳定性，可更好地用于临床治疗。

Description

PCT国内申请，说明书已公开。

Claims (32)

  1. PCT国内申请，权利要求书已公开。
CN201880059079.1A 2017-10-25 2018-10-24 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法 Active CN111108098B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201711008888 2017-10-25
CN2017110088883 2017-10-25
CN201711261104 2017-12-04
CN2017112611048 2017-12-04
PCT/CN2018/111630 WO2019080865A1 (zh) 2017-10-25 2018-10-24 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN111108098A true CN111108098A (zh) 2020-05-05
CN111108098B CN111108098B (zh) 2022-06-21

Family

ID=66246215

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059079.1A Active CN111108098B (zh) 2017-10-25 2018-10-24 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法

Country Status (13)

Country Link
US (1) US11014888B2 (zh)
EP (1) EP3702350A4 (zh)
JP (1) JP2021500315A (zh)
KR (1) KR20200077531A (zh)
CN (1) CN111108098B (zh)
AU (1) AU2018355472A1 (zh)
BR (1) BR112020007499A2 (zh)
CA (1) CA3076557A1 (zh)
MX (1) MX2020004388A (zh)
RU (1) RU2020111829A (zh)
TW (1) TW201917117A (zh)
UA (1) UA125565C2 (zh)
WO (1) WO2019080865A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110240562A (zh) * 2018-03-08 2019-09-17 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020021850A1 (ja) * 2018-07-25 2020-01-30 富士フイルム株式会社 投影装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110240562A (zh) * 2018-03-08 2019-09-17 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
CN110240562B (zh) * 2018-03-08 2022-04-12 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
KR20200077531A (ko) 2020-06-30
RU2020111829A (ru) 2021-11-25
UA125565C2 (uk) 2022-04-20
WO2019080865A1 (zh) 2019-05-02
TW201917117A (zh) 2019-05-01
CN111108098B (zh) 2022-06-21
US20200299240A1 (en) 2020-09-24
EP3702350A4 (en) 2021-03-17
EP3702350A1 (en) 2020-09-02
BR112020007499A2 (pt) 2020-10-06
JP2021500315A (ja) 2021-01-07
MX2020004388A (es) 2020-08-20
CA3076557A1 (en) 2019-05-02
US11014888B2 (en) 2021-05-25
AU2018355472A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
KR102162208B1 (ko) 7-((3s,4s)-3-[(사이클로프로필아미노)메틸]-4-플루오로피롤리딘-1-일)-6-플루오로-1-(2-플루오로에틸)-8-메톡시-4-옥소-1,4-다이하이드로퀴놀린-3-카복실산 결정
KR101806346B1 (ko) 티피라실 염산염의 안정형 결정 및 그 결정화 방법
CN111108098B (zh) 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
CN108779122B (zh) 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
JP2018502140A (ja) ベンズイミダゾール誘導体の新規結晶形及びその製造方法
WO2008013823A2 (en) Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide
CN110028497B (zh) 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法
TWI762825B (zh) 酪胺酸激酶抑制劑的一馬來酸鹽的晶型及其製備方法
CN110240562B (zh) 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
JP2017530107A (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
CN109912509B (zh) 一种雄性激素受体抑制剂的晶型及其制备方法
TW201908320A (zh) 一種ｂｔｋ激酶抑制劑的結晶形式及製備方法
CN112020489B (zh) 2-(2,5-二氧代吡咯烷-1基)乙基甲基富马酸酯的晶型a及其制备方法和应用
WO2024009977A1 (ja) ５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン及びその塩体の結晶
EP2042498A1 (en) Crystal of benzoxadiazole derivative
CN111138414A (zh) 一种酪氨酸激酶抑制剂的晶型及其制备方法
CN116283919A (zh) Vimseltinib的新晶型及其制备方法
CN115433246A (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
CN113651689A (zh) S-氟比洛芬钠新晶型及其制备方法
CN117800941A (zh) 一种苯并吡喃类化合物的晶型及其制备方法
CN116262697A (zh) 一种氟比洛芬和精氨酸的共晶及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40024614

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant